Heroin Dependence Clinical Trial
— THEDOfficial title:
Efficacy of Repetitive Transcranial Magnetic Stimulation and Cognitive Behavioral Therapy on Heroin Dependence
Heroin dependence is one of most common substance dependence, which brings great burden on health worldwide. Heroin dependence may lead to immunosuppression and cognitive impairments. Once heroin dependence is developed, it will be difficult to recover and easy to relapse. Although many efforts had been made in the treatment of heroin dependence, the annual recurrence of heroin dependence with traditional therapies would be up to 90%. Repetitive transcranial magnetic stimulation (rTMS) on the dorsolateral prefrontal cortex (DLPFC) or cognitive behavioral therapy (CBT) each alone was reported to have some effect on preventing from relapse of substance dependence. In order to test whether combined therapy of high frequency rTMS (hf-rTMS) with CBT is better for preventing from relapse of heroin dependence, we recruit patients with heroin dependence to participate this study. The study is a factorial designed and the patients will be assigned into one of the following six groups randomly: (1) regular treatment (symptomatic treatment) with blank TMS; (2) regular treatment (RT) with blank TMS and CBT; (3) RT with right DLPFC hf-rTMS; (4) RT with right DLPFC hf-rTMS and CBT; (5) RT with left DLPFC hf-rTMS; (6) RT with left DLPFC hf-rTMS and CBT. TMS was given 5 days per week for total 2 weeks using uniform scheme (5 seconds of 10Hz stimulation per train, 30 trains per day with inter-train interval of 20 seconds). CBT will be given once per week for total 8 weeks. The patients will be followed up for 6 months. Recurrence of heroin dependence, duration of abstention, heroin/drug intake, craving for heroin and other cognitive psychological assessments will be recorded and compared among the 6 treatment groups and the efficacy of combined therapy of rTMS with CBT will be evaluated in our study.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | December 2021 |
Est. primary completion date | December 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Diagnosis as heroin dependence according to DSM-IV criteria - No definite history of neurological diseases and psychological problems - Volunteer to participate the study, cooperate to be followed up Exclusion Criteria: - Acute withdrawal state and CIWA score > 9 - With other neurological diseases and psychological problems - With ever brain trauma and damage - With other psychological medications or other substance dependence - With other contraindications to have transcranial magnetic stimulation |
Country | Name | City | State |
---|---|---|---|
China | Sun Yat-sen Memorial Hospital, Sun Yat-sen University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
China,
Herremans SC, Vanderhasselt MA, De Raedt R, Baeken C. Reduced intra-individual reaction time variability during a Go-NoGo task in detoxified alcohol-dependent patients after one right-sided dorsolateral prefrontal HF-rTMS session. Alcohol Alcohol. 2013 Sep-Oct;48(5):552-7. doi: 10.1093/alcalc/agt054. Epub 2013 May 24. — View Citation
Makani R, Pradhan B, Shah U, Parikh T. Role of Repetitive Transcranial Magnetic Stimulation (rTMS) in Treatment of Addiction and Related Disorders: A Systematic Review. Curr Drug Abuse Rev. 2017;10(1):31-43. doi: 10.2174/1874473710666171129225914. Review. — View Citation
Phillips MR, Zhang J, Shi Q, Song Z, Ding Z, Pang S, Li X, Zhang Y, Wang Z. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001-05: an epidemiological survey. Lancet. 2009 Jun 13;373(9680):2041-53. doi: 10.1016/S0140-6736(09)60660-7. — View Citation
Shen Y, Cao X, Tan T, Shan C, Wang Y, Pan J, He H, Yuan TF. 10-Hz Repetitive Transcranial Magnetic Stimulation of the Left Dorsolateral Prefrontal Cortex Reduces Heroin Cue Craving in Long-Term Addicts. Biol Psychiatry. 2016 Aug 1;80(3):e13-4. doi: 10.1016/j.biopsych.2016.02.006. Epub 2016 Feb 12. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recurrence of heroin dependence | The rate of relapse of heroin dependence after discharge from hospital | 1 month | |
Primary | Recurrence of heroin dependence | The rate of relapse of heroin dependence after discharge from hospital | 2 month | |
Primary | Recurrence of heroin dependence | The rate of relapse of heroin dependence after discharge from hospital | 3 month | |
Primary | Recurrence of heroin dependence | The rate of relapse of heroin dependence after discharge from hospital | 6 month | |
Secondary | Duration of abstinence | The total time or period without any intake of heroin during follow-ups | 6 months | |
Secondary | Heroin consumption | Diaries of heroin intake in different time of the follow-ups | 2 weeks, 1 month, 2 months, 3 months and 6 months | |
Secondary | Craving for heroin | Craving assessment for heroin by Heroin Craving Questionnaire (HCQ) ranging from 0 to 175. Higher score of HCQ indicates more desire for heroin. | 2 weeks, 1 month, 2 months, 3 months and 6 months | |
Secondary | Craving for heroin | Craving assessment by Visual Analogue Scale (VAS) for heroin desire ranging 0 to 10. Higher score indicates more desire for heroin. | 2weeks, 1 month, 2 months, 3 months and 6 months | |
Secondary | Cognitive assessment | Cognitive assessment by Montreal Cognitive Assessment (MoCA) ranging from 0 to 30. Lower score indicates worse cognitive function. | 2 weeks, 1 month, 2 months, 3 months and 6 months | |
Secondary | Psychological assessment - Anxiety | Psychological assessment by Generalized Anxiety Disorder-7 (GAD-7) ranging from 0 to 21. Higher score indicates more severer anxiety. | 2 weeks, 1 month, 2 months, 3 months and 6 months | |
Secondary | Psychological assessment - Depression | Psychological assessment by Patient Health Questionnaire-9 (PHQ-9) ranging from 0 to 27. Higher score indicates more severer depression. | 2 weeks, 1 month, 2 months, 3 months and 6 months | |
Secondary | Psychological assessment - Sleep | Psychological assessment by Pittsburgh Sleep Quality Index (PSQI) ranging from 0 to 21. Higher score indicates worse sleep. | 2 weeks, 1 month, 2 months, 3 months and 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00577408 -
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
|
Phase 3 | |
Completed |
NCT00218309 -
Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals
|
Phase 2 | |
Completed |
NCT00000211 -
Treatment Efficacy for Drug Abuse and AIDS Prevention - 2
|
Phase 2 | |
Completed |
NCT00000210 -
Treatment Efficacy for Drug Abuse and AIDS Prevention - 1
|
Phase 2 | |
Completed |
NCT02324725 -
Biomarkers of Injectable Extended Release Naltrexone Treatment
|
Phase 4 | |
Withdrawn |
NCT00000330 -
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5
|
Phase 2 | |
Completed |
NCT00249457 -
Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 2
|
N/A | |
Completed |
NCT00218127 -
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
|
Phase 2 | |
Completed |
NCT04133974 -
Methadone Induced Memory Retrieval-extinction Procedure in Heroin Addicts
|
N/A | |
Completed |
NCT00015288 -
Buprenorphine and Naloxone Combination Study - 10
|
Phase 1 | |
Terminated |
NCT03711318 -
Buprenorphine Stabilization and Induction Onto Vivitrol for Heroin-dependent Individuals
|
Phase 3 | |
Recruiting |
NCT02541526 -
Mirtazapine as a Treatment for Co-Occurring Opioid and ATS Dependence in Malaysia
|
Phase 3 | |
Active, not recruiting |
NCT02541513 -
An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS Dependence
|
Phase 3 | |
Completed |
NCT01760473 -
Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone
|
Phase 3 | |
Terminated |
NCT01395797 -
Pioglitazone for Heroin and for Nicotine Dependence
|
Phase 1/Phase 2 | |
Completed |
NCT01668706 -
Pharmacogenomics Study of Sleep Disturbance and Neurocognitive Impairments in the Opioid Addicts
|
N/A | |
Active, not recruiting |
NCT00609089 -
Community Reinforcement and Family Training for Drug Abuse Treatment Retention/HIV Risk Reduction
|
Phase 1/Phase 2 | |
Completed |
NCT00684840 -
Effects of Stress and Other Factors on Opiate Drug Choice.
|
N/A | |
Completed |
NCT00759005 -
Effect of Stress on Heroin-Related Memory Retrieval
|
N/A | |
Completed |
NCT00218530 -
Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1
|
Phase 1 |